Variants of uncertain significance fundamentally limit the clinical utility of genetic information. The challenge they pose is epitomized by BRCA1, a tumour suppressor gene in which germline loss-of-function variants predispose women to breast and ovarian cancer. Although BRCA1 has been sequenced in millions of women, the risk associated with most newly observed variants cannot be definitively assigned. Here we use saturation genome editing to assay 96.5% of all possible single-nucleotide variants (SNVs) in 13 exons that encode functionally critical domains of BRCA1. Functional effects for nearly 4,000 SNVs are bimodally distributed and almost perfectly concordant with established assessments of pathogenicity. Over 400 non-functional missense SNVs are identified, as well as around 300 SNVs that disrupt expression. We predict that these results will be immediately useful for the clinical interpretation of BRCA1 variants, and that this approach can be extended to overcome the challenge of variants of uncertain significance in additional clinically actionable genes.
Over 400 non-functional missense SNVs are identified, as well as around 300 SNVs that disrupt expression. We predict that these results will be immediately useful for the clinical interpretation of BRCA1 variants, and that this approach can be extended to overcome the challenge of variants of uncertain significance in additional clinically actionable genes.
Our ability to predict the phenotypic consequences of an arbitrary genetic variant in a human genome remains poor. This problem is evidenced by the large numbers of variants of uncertain significance (VUS) identified in 'actionable' genes, that is, genes in which the definitive identification of a pathogenic variant would alter clinical management 1 . For example, heterozygous germline variants that disrupt BRCA1 markedly increase the risk of early-onset breast and ovarian cancer 2, 3 and are actionable, as more frequent screening or prophylactic surgery can lead to improved outcomes 4, 5 . Clinical sequencing can identify specific variants as risk-conferring 6 . However, as of January 2018, most BRCA1 SNVs are classified as VUS 7 . VUS are typified by rare missense SNVs, but also include variants potentially affecting messenger RNA (mRNA) levels. Further illustrating the challenge associated with VUS, there are hundreds of BRCA1 SNVs that have received conflicting interpretations 7 . There are two main approaches for resolving VUS. The first approach, data sharing, relies on the expectation that as BRCA1 is sequenced in more individuals, the recurrent observation of a variant in individuals who either have or have not developed cancer will enable its interpretation. However, given that the majority of potential variants in BRCA1 are extremely rare and that the phenotype is incompletely penetrant, it is unclear whether sufficient numbers of humans will ever be sequenced to accurately quantify cancer risk for each possible variant.
The second approach, functional assessment, has spurred the development of diverse in vitro assays for BRCA1 8 . As the homology-directed DNA repair (HDR) function of BRCA1 is key for tumour suppression, one commonly used assay measures whether expression of a BRCA1 variant can rescue HDR integrity 9, 10 . Other BRCA1 assays evaluate embryonic stem cell viability 11 , transcriptional activation 12 , drug sensitivity 11 , protein-protein interaction 9, 13 or splicing 14, 15 . Computational predictions based on features such as conservation can be informative but are insufficiently accurate to be used in the absence of genetic or experimental evidence 16 . Experimental assessments of BRCA1 variants have been limited in several ways. First, they are typically performed post hoc and have not kept pace with the discovery of VUS. Second, assays expressing variants as cDNA-based transgenes removed from their genomic context 9, 13 fail to assess the effects on splicing or transcript stability, and risk artefacts of overexpression 17 . Genome editing provides a potential means to overcome these challenges, but has yet to be applied to characterize any appreciable number of VUS in BRCA1 or other genes similarly linked to cancer predisposition.
Here we set out to apply genome editing to measure the functional consequences of all possible SNVs in key regions of BRCA1, regardless of whether they have been previously observed in a human. Given the large size of BRCA1, we prioritized 13 exons that encode the RING and BRCT domains, which critically underlie its role as a tumour suppressor [18] [19] [20] . In addition to around 400 VUS or variants with conflicting interpretations, all 21 BRCA1 missense SNVs classified by a ClinVar-approved expert panel as pathogenic reside in these exons 7 , as do missense and splice variants shown to disrupt BRCA1 in functional assays 11, 21 (ClinVar is a widely used database of clinical variant interpretations submitted by clinical testing laboratories). In each experiment, a single exon is subjected to saturation genome editing (SGE) 22 , wherein all possible SNVs are simultaneously introduced and concurrently assayed. We used SGE to measure functional effects for 3,893 SNVs, comprising 96.5% of all possible SNVs in the targeted exons. These scores are bimodally distributed and nearly perfectly concordant with expert-based assessments of pathogenicity. We predict that our functional classifications will be of immediate clinical utility, and that scaling this approach to additional genes will substantially enhance the utility of genetic testing.
Article reSeArcH the edited loci of BRCA1-targeted cells confirmed that cell death was consequent to mutations, as there was widespread selection against frameshifting indels (Extended Data Fig. 1d ). Overall, these results confirm the importance of HDR pathway components in HAP1 cells.
We next designed and optimized experiments for SGE 22 ( Fig. 1b) , focusing on the 13 exons of BRCA1 that encode the RING and BRCT domains (exons 2-5 and 15-23, respectively; NCBI, NM_007294.3). To create libraries of repair templates, we used array-synthesized oligonucleotide pools containing all possible SNVs spanning each exon and around 10 base pairs (bp) of adjacent intronic sequence. Oligonucleotide pools for each exon were cloned into plasmids with homology arms ('SNV libraries'). Each design also included a fixed synonymous substitution at the Cas9 target site to reduce re-cutting after successful HDR 22 . Each SGE experiment targeted one exon. A population of 20 million HAP1 cells was co-transfected on day 0 with a corresponding SNV library and Cas9/gRNA plasmid. Variant frequencies were quantified by targeted sequencing of the edited exon from genomic DNA (gDNA) collected on day 5 and day 11.
We initially performed SGE in replicate for each exon in wild-type HAP1 cells. In each exon, we observed the expected depletion of frameshifting indels (Extended Data Fig. 2) . However, to achieve more robust data, we optimized SGE in HAP1 cells in two ways. First, to increase HDR rates 25 , we generated a monoclonal LIG4-knockout HAP1 line (HAP1-LIG4 KO ) (Extended Data Fig. 3a, g ). Second, as HAP1 cells can spontaneously revert to diploidy 26 , sorting HAP1 cells for 1n ploidy before editing improved reproducibility (Extended Data  Fig. 3b, h ).
We performed optimized SGE on each of the 13 exons in 1n-sorted HAP1-LIG4 KO cells. We observed a median 3.6-fold increase in HDR rates on day 5 in HAP1-LIG4 KO relative to wild-type HAP1 cells (Fig. 2a) , allowing us to test nearly every SNV in replicate (Extended Data Fig. 3c ). Because these optimizations increased reproducibility without substantially altering SNV effects on survival (Fig. 2b,  Extended Data Figs. 3, 4) , we proceeded with data from the 1n-sorted HAP1-LIG4 KO cells. Additionally, targeted RNA sequencing of day 5 HAP1-LIG4 KO samples was used to determine the abundance of exonic SNVs in BRCA1 mRNA (Fig. 2c) .
Function scores for 3,893 BRCA1 SNVs
To calculate function scores for each SNV, we first calculated the log 2 ratio of the frequency of a SNV on day 11 to its frequency in the plasmid library. Second, positional biases in editing rates were modelled using day 5 SNV frequencies and subtracted (Extended Data Fig. 5 ). Third, to enable comparisons between exons, we normalized function scores such that the median synonymous and nonsense SNV in each experiment matched global medians. Lastly, a small number of SNVs that could not confidently be scored were filtered out (Extended Data  Fig. 6 ). Altogether, we obtained function scores for 3,893 SNVs, which comprise 96.5% of all possible SNVs within or immediately intronic to these exons (Supplementary Table 1 ; https://sge.gs.washington.edu/ BRCA1/).
Function scores were bimodally distributed (Fig. 2d ). All nonsense SNVs scored below −1.25 (n = 138, median = −2.12), whereas 98.7% of synonymous SNVs more than 3 bp from splice junctions scored above −1.25 (n = 544, median = 0.00). We classified all SNVs as 'functional' , 'non-functional' , or 'intermediate' by fitting a two-component Gaussian mixture model (Extended Data Fig. 7) . We categorized 72.5% of SNVs as functional, 21.1% as non-functional and 6.4% as intermediate.
It is particularly challenging to interpret the clinical importance of rare missense variants in BRCA1. Of the missense SNVs assayed, 21.1% (441 out of 2,086) were non-functional (Fig. 2e) . Although most remaining missense SNVs were functional (70.6%), there was an enrichment for missense SNVs with intermediate effects (8.1% compared with 4.4% of all other SNVs; Fisher's exact test, P = 2.7 × 10
−6
). An advantage of genome editing is that the effect of variants on native regulatory mechanisms such as splicing can be ascertained 22 . Whereas SNVs disrupting canonical splice sites (the two intronic positions immediately flanking each exon) were mostly non-functional (89.5%) or intermediate (5.5%) (Fig. 2e) , SNVs positioned 1-3 bp into the exon or 3-8 bp into the intron had variable effects. We defined SNVs in these regions that did not alter the amino acid sequence as 'splice region' variants, of which 22.9% were non-functional (Fig. 2e) . SNVs positioned more deeply in introns or in the 5′ untranslated region (UTR) were similar to non-splice-region synonymous SNVs, in that they were much less likely to score as non-functional (intronic, 1.8%; 5′ UTR, 0.0%; and synonymous, 1.3%, as non-functional).
Function scores accurately predict pathogenicity
We next investigated how well our function scores agreed with clinical variant interpretations present in ClinVar. Of 169 SNVs deemed 'pathogenic' in ClinVar that overlapped with our classifications, 162 were designated 'non-functional' , two 'functional' , and the remaining five 'intermediate' . By contrast, of 22 SNVs deemed 'benign' in ClinVar, 20 were designated 'functional' , one 'non-functional' , and one 'intermediate' (Fig. 3a) . Three SNVs that scored unambiguously discordant with ClinVar suggest potential errors in the available clinical variant interpretations (Supplementary Note 1) . A receiver operating 23 of HDR pathway genes (n = 66) among 14,306 genes scored in a HAP1 gene trap screen for essentiality are indicated with tick marks. Essential HDR genes are coloured red and those implicated in cancer predisposition are labelled in the enlargement below. Of the 66 HDR pathway genes scored, 34 including BRCA1 were 'essential' , a 3.4-fold enrichment compared to non-HDR genes (Fisher's exact test, P = 6.1 × 10 −12 ). b, SGE experiments were designed to introduce all possible SNVs across 13 BRCA1 exons encoding the RING (exons 2-5, NCBI, NM_007294.3) and BRCT domains (exons [15] [16] [17] [18] [19] [20] [21] [22] [23] . The exonic locations of all 21 BRCA1 missense variants in ClinVar deemed pathogenic by an expert panel are indicated by red ovals. For each exon, a Cas9/ gRNA construct was transfected with a library of plasmids containing all SNVs within approximately 100 bp of genomic sequence (the 'SNV library'). SNV library plasmids contained homology arms, as well as fixed synonymous variants within the CRISPR target site to prevent re-cutting. Upon transfection, successfully edited cells carried a single BRCA1 SNV from the library. Cells were sampled 5 and 11 days after transfection and targeted gDNA and RNA sequencing was performed to quantify SNV abundances. SNVs compromising BRCA1 function were selected against, manifesting in reduced gDNA representation, and SNVs that affect mRNA production were depleted in RNA relative to gDNA.
Article reSeArcH characteristic (ROC) curve showed a sensitivity of 96.7% at 98.2% specificity when we treat 'likely pathogenic' and 'likely benign' ClinVar annotations as pathogenic and benign, respectively (Fig. 3b) . Importantly, sensitivity and specificity are high for missense and splice region SNVs (Extended Data Fig. 7f) .
We scored 25.0% (64 out of 256) of VUS and 49.2% (60 out of 122) of SNVs with conflicting interpretations as non-functional (Fig. 3c) . Missense VUS from ClinVar were more likely to score as non-functional than missense SNVs that were absent from ClinVar (25.9% compared with 17.2%, Fisher's exact test, P = 0.002). Of 3,140 assayed SNVs that were absent from ClinVar, 498 (15.9%) scored as non-functional. The distribution of function scores for the 29 firmly 'pathogenic' missense SNVs confirmed here to be non-functional does not significantly differ from that of the 296 non-functional missense SNVs absent from ClinVar (median −2.05 versus −1.97; Wilcoxon rank-sum test, P = 0.35).
We investigated the relationship between our function scores and allele frequencies in large-scale variant databases, such as gnomAD (The Genome Aggregation Database; whole-exome and whole-genome sequencing data from over 120,000 individuals) 27 . Among 302 assayed SNVs that overlap with gnomAD, higher allele frequencies were associated with higher function scores (Extended Data Fig. 8a ). For instance, 33 out of 166 (19.9%) of singleton variants were non-functional, whereas only 8 out of 136 (5.9%) non-singleton variants were nonfunctional (Fisher's exact test, P = 3 × 10 −4 ). A similar trend was observed with the Bravo database (Extended Data Fig. 8b ). The FLOSSIES database contains variants observed in around 10,000 women over seventy years old who have not developed breast or ovarian cancer (https://whi.color.com/gene/ENSG00000012048). Of 39 intersecting BRCA1 SNVs in FLOSSIES, only one scored as nonfunctional (Extended Data Fig. 8c ). Collectively, these observations confirm that BRCA1 SNVs with higher allele frequencies are more likely to be functional.
Several computational metrics are currently used to the assess deleteriousness of variants and are often included in genetic testing reports. Although our function scores correlate with metrics such as CADD 28 , phyloP 29 and Align-GVGD 30 , the modesty of these correlations underscores the value of functional assays (Fig. 3d, Extended Data Fig. 9a-g ). ROC curve analysis restricted to the 46 missense SNVs deemed 'pathogenic' or 'benign' in ClinVar reveals that SGE function scores outperform these metrics (Extended Data Fig. 9h-l) . Article reSeArcH SGE function scores also strongly correlate with the results of assays designed to test particular aspects of BRCA1 activity. For example, they are highly concordant with assays specific for the role of BRCA1 in HDR 9,13,31 and transcriptional activation 12 (Extended Data Fig. 9m , n), as well as with the results of a multiplexed assay that assesses the function of BRCA1 variants in HDR 32 .
Mechanisms of BRCA1 loss-of-function
To gain insights into the various mechanisms by which SNVs in BRCA1 compromise function, we performed targeted RNA sequencing of BRCA1 transcripts from edited day 5 cells. We normalized SNV frequencies in cDNA to their frequencies in gDNA to produce mRNA expression scores ('RNA scores') for 96% of the functionally characterized exonic SNVs. Together with function scores, RNA scores enable fine mapping of molecular consequences of SNVs (Fig. 4) .
Overall, 89% of non-functional missense SNVs did not reduce RNA levels substantially, suggesting that their effects are mediated at the protein level (Fig. 5a , Supplementary Note 2). Many residues that are sensitive to missense SNVs that do not affect RNA levels map to buried hydrophobic residues or to the zinc-coordinating loops required for RING domain folding 33 ( Fig. 5b, c) . For example, 20 out of 21 missense SNVs in c.5104-c.5112 were scored as non-functional, including four VUS (Fig. 4) . This intolerance to variation is probably due to the hydrophobicity and internal position of Y1703 and F1704, and the polar contacts made between K1702 and a phosphorylated binding partner 34 . This contrasts with a 51-bp stretch spanning exons 21 and 22 (c.5368-c.5418, p.1790-1806) in which none of the 104 missense SNVs assayed were non-functional.
SGE also implicates numerous SNVs that affect expression. For example, all SNVs that disrupt the translation initiation codon score as non-functional, and certain SNVs at the −3, +4 and +5 positions predicted to decrease translational efficiency 35 score as intermediate or non-functional. In addition, 11% of non-functional missense SNVs are depleted from RNA by at least 75%, many of which map to unstructured regions (Fig. 5b, c) , suggesting loss-of-function is consequent to reduced mRNA levels rather than disrupted protein function. Consistent with this, the 12 synonymous SNVs classified as nonfunctional also tended to markedly reduce mRNA levels (median 5.4-fold reduction).
Variants depleted in mRNA probably affect RNA splicing. This is evidenced by an overrepresentation of non-functional exonic SNVs near splice junctions, including low scores for many SNVs at terminal G nucleotides of exons (Fig. 4) , non-functional exonic SNVs with low mRNA levels that create new acceptor or donor sequences (Fig. 5d) , and the presence of 6-8 bp regions wherein many SNVs have strong effects on mRNA levels, suggestive of exonic splice enhancers 36 (Extended Data Fig. 10a ). Certain exons were particularly prone to harbour non-functional SNVs with low RNA scores. In exon 16, for 4891  4900  4910  4920  4930  4940  4950  4960  4970  4980  4986  4986+10   213  213−10  220  230  240  250  260  270  280  290  301  301+10   135  135−10  140  150  160  170  180  190  200  212  212+10   81  81-20  81-10  90  100  110  120  130  134  134+10  134+20   1  -19  -10  10  20  30  40  50  60  70 80 Article reSeArcH instance, 46 of 244 SNVs (excluding nonsense) were non-functional (Extended Data Fig. 10a ). Most of these (26 out of 46) reduced RNA levels by ≥2-fold, and 15 by ≥4-fold. By contrast, in exon 19, 55 of 234 SNVs (excluding nonsense) were non-functional, but none lowered expression by ≥2-fold (Extended Data Fig. 10b ). Exon 19 also completely lacks non-functional SNVs in its flanking intronic regions (apart from the acceptor and donor sites), suggesting it is robustly spliced.
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Discussion
Here we applied SGE to critical domains of BRCA1, characterizing the consequences of nearly 4,000 SNVs in their native genomic context and obtaining a bimodal distribution of functional effects. A benefit of functional data is that measurements are systematically derived, independent of prior expectation 37 . Because we measured cell survival, the effects of SNVs on multiple layers of gene function (for example, splicing, translation, and protein activity) are effectively integrated. Our study has several caveats (Supplementary Note 3), most notably that we used a survival assay in HAP1 cells as opposed to a more physiologically appropriate model. However, our data are validated by high concordance with the available evidence for clinical pathogenicity.
High sensitivity and specificity were obtained for both missense and splice region SNVs, the classes of variants that are most problematic for clinical interpretation. Our review of firmly discordant SNVs suggests that our true accuracy may be higher than calculated using ClinVar assertions as a gold standard (Supplementary Note 1) . These discordances highlight the importance of integrating new evidence as it becomes available and updating databases accordingly. For instance, the submissions in the Breast Cancer Information Core, which mostly date to the early 2000s, underlie 51 conflicting interpretations. SGE scores support the more recent classification in the vast majority of such conflicts (Supplementary Table 2 ).
The interpretation of genetic variation is presently the rate-limiting step for genomic medicine. The fact that more than 70% of ClinVar variants and more than 95% of non-ClinVar variants assayed here have never been observed in more than 120,000 humans represented in gnomAD illustrates the challenges facing observational approaches to variant interpretation. Given this, a pressing question is how best to integrate functional data into existing clinical variant classification schemes 38 . The predictive power demonstrated here suggests that SGE function scores classify variants with more than 95% accuracy. As current standards for defining 'likely' pathogenic and benign variants accept comparable uncertainty 39 , we argue that a failure to incorporate function scores would be a missed opportunity.
Optimal weighting of different approaches might further improve classification of variants lacking genetic evidence. For unexpected functional classifications, such as synonymous SNVs with low scores, and for cases in which the clinical evidence is contradictory, functional data can provide specific hypotheses to test. For example, c.5044G>A, for which our data contradicts ClinVar, could be disambiguated by testing BRCA1 mRNA levels in individuals carrying this SNV. The approximately 6% of SNVs exhibiting intermediate function scores remain beyond definitive interpretation. The fact that we observe an excess of missense SNVs with intermediate scores suggests that some of these may be hypomorphic BRCA1 alleles 40 . Further studies will be necessary to assess the risk conferred by these variants.
We prioritized the RING and BRCT domains, but SGE of all exons of BRCA1 is justified, and the essentiality of BRCA2, PALB2, BARD1 and RAD51C in HAP1 cells suggests that these genes are assayable by the same method. For other genes, assays compatible with saturation genome editing (for example, drug selection, FACS on phenotypic markers) may need to be developed and validated. Scaling SGE to many loci also promises to improve our understanding of how diverse biological functions are encoded by the genome.
Here we show that SGE is a viable strategy for functionally classifying thousands of variants in a clinically actionable gene, most of which have yet to be observed in a human. We anticipate function scores will prove valuable, both for adjudicating hundreds of observed BRCA1 variants for which the interpretation is currently ambiguous, as well as ... . gRNA design and cloning. All CRISPR gRNAs used in SGE and essentiality experiments were cloned into pX459 24 . This plasmid expresses the gRNA from a U6 promoter, as well as a Cas9-2A-puromycin resistance (-puroR) cassette. S. pyogenes Cas9 target sites were chosen for SGE experiments on multiple criteria, assessed in the following order: (i) to induce cleavage within BRCA1 coding sequence, (ii) to target a genomic site permissive to synonymous substitution within the guanine dinucleotide of the PAM or the protospacer, (iii) to have minimal predicted offtarget activity 43 , (iv) to have maximal predicted on-target activity 44 .
Complementary oligonucleotides ordered from Integrated DNA Technologies (IDT) were annealed, phosphorylated, diluted and ligated into BbsI-digested and gel-purified pX459, as described previously 24 . Ligation reactions were transformed into Escherichia coli (Stellar competent cells, Takara), which were plated on ampicillin. Colonies were cultured and Sanger-sequenced to confirm correct gRNA sequences. Purification of sequence-verified plasmids for transfection was performed with the ZymoPure Maxiprep kit (ZymoResearch). For targeting LIG4 in HAP1 cells, pX458 24 was used instead of pX459, which expresses EGFP in lieu of puroR. HDR library design and cloning. Array-synthesized oligonucleotides were designed as follows for each saturation genome editing region (that is, a BRCA1 exon). The sequence to be mutated (~100 bp) was obtained from the human genome (hg19) and a synonymous substitution was introduced at the chosen Cas9 target site (for example, a substitution at the PAM site). This 'fixed' substitution in the library was included in design to serve multiple purposes: (i) plasmid library molecules harbouring the substitution are predicted to be cleaved less frequently by Cas9-gRNA complexes, (ii) SNVs introduced to cells are predicted to be depleted via Cas9 re-cutting less frequently as a consequence of the fixed substitution, and (iii) sequencing reads can be filtered on the fixed substitution to distinguish true SNVs introduced via HDR from sequencing errors. A second synonymous substitution at an alternative CRISPR target site was introduced to the sequence as well, such that the SNV library for each exon would be compatible with multiple gRNAs. Next, a sequence was created for every single nucleotide substitution on this template. For all sequences, adapters were added to both ends to enable PCR amplification from the oligonucleotide pool. For each SGE region, the total number of oligonucleotides designed was three times the length of the region, plus the oligonucleotide template without any SNV (for example, for a 100-bp SGE region, 301 total oligonucleotides were designed).
Pooled oligonucleotides were synthesized (Agilent Technologies). Primers designed to amplify the subset of oligonucleotides corresponding to a single region of an exon were used to perform PCR with Kapa HiFi Hot-start Ready Mix (Kapa HiFi, Kapa Biosystems). PCR products were purified with Ampure beads (Agencourt) to be used in subsequent library cloning reactions.
Homology arms were cloned into pUC19 by PCR-amplifying (Kapa HiFi) regions surrounding each targeted exon from HAP1 gDNA. Primers for these reactions were designed such that homology arms would be between 600 bp and 1,000 bp on both sides of the targeted region. Adapters homologous to pUC19 were added to primers to facilitate NEBuilder HiFi Assembly cloning (NEB) into a linearized pUC19 vector. Cloning reactions were transformed into Stellar competent cells and selected with ampicillin. Plasmid DNA was isolated from colonies (Qiagen MiniPrep kit) and sequence-verified.
To construct the HDR library, homology arm plasmids were linearized via PCR using primers that conferred 15-20 bp of terminal overlap with the adapter sequences flanking each PCR-amplified oligonucleotide pool. This sequence overlap enabled cloning via the NEBuilder HiFi Assembly Cloning Kit (NEB). Cloning reactions were transformed into Stellar competent cells, and a small proportion (1%) of the transformation was plated on ampicillin-containing plates to assess efficiency. All remaining transformed cells were grown directly in 100 ml of medium with ampicillin for 16-18 h, and plasmid DNA from the culture was isolated (ZymoPure Maxiprep kit) to produce each final HDR library.
HAP1 cell culture. Quality-controlled wild-type HAP1 cells were purchased (Haplogen/Horizon Discovery) and cultured in medium comprising Iscove's Modified Dulbecco's Medium (IMDM) with l-glutamine and 25 mM HEPES (GIBCO) supplemented with 10% fetal bovine serum (Rocky Mountain Biologicals) and 1% penicillin-streptomycin (GIBCO). Cells were grown on plates at 37 °C with 5% CO 2 , and passaged before becoming confluent. For routine passaging, cells were washed once with 1× phosphate-buffered saline (PBS, Gibco), trypsinized with 0.25% trypsin with EDTA (Gibco), resuspended in medium, centrifuged for 5 min at 300g, and then resuspended and plated.
A monoclonal LIG4-knockout HAP1 line (HAP1-LIG4 KO ) was generated by transfecting a plasmid expressing a Cas9-2A-GFP cassette and a gRNA targeting the human LIG4 coding sequence (gRNA sequence: 5′-GCATAATGT CACTACAGATC-3′) into wild-type HAP1 cells. Single GFP-expressing HAP1 cells were sorted into wells of a 96-well plate and cultured. After two weeks, gDNA was collected and Sanger sequencing was performed to assess LIG4 editing. A clone with a 4-bp deletion was identified and expanded further for use in saturation genome editing experiments.
HAP1 cells can spontaneously revert to a diploid state in cell culture. Therefore, to sort a 1n-enriched population of cells before transfection, cells were stained for DNA content with Hoechst 34580 (BD Biosciences) at 5 μg ml −1 medium for 1 h at 37 °C. FACS was performed to isolate 1-2 × 10 6 cells from the lowest intensity Hoechst peak, corresponding to 1n ploidy. These cells were expanded for seven days before transfection. Transfection of HAP1 cells. For all experiments, HAP1 cells were transfected using TurboFectin 8.0 (Origene) according to manufacturer's protocol. A 2.5× volume of Turbofectin was added to the transfection mix for each μg of plasmid DNA in Opti-Mem (Life Technologies). For each SGE transfection, 10 million cells were passaged to a 10-cm dish. The next day (day 0), cells were co-transfected with 12 μg of the Cas9/gRNA plasmid (pX459) and 3 μg of the SNV library corresponding to a single exon. Negative control transfections were performed for each library using a pX459 vector targeting HPRT1 instead of BRCA1, thus preventing genomic integration of the library. On day 1, cells were passaged into medium supplemented with puromycin (1 μg ml −1 ) to select for successfully transfected cells. On day 4, cells were washed twice and passaged to 6-cm plates in regular media.
Cell populations were sampled on day 5 and day 11 for all SGE experiments. On day 5, half of the cells were pelleted and frozen and the other half passaged. The cells were passaged on day 8 into 15-cm dishes and then harvested on day 11. Negative control transfections were harvested on day 5 and used to confirm that PCR amplicons were not derived from the plasmid DNA of the SNV library.
For the luminescence-based viability assay, HAP1 cells were plated at 35-40% confluency in a 6-well dish (approximately 1.2 million cells per well per target) then transfected with 1.5 μg Cas9/gRNA plasmid targeting coding exons of HDR genes or controls the following day. After 24 h of transfection, the cells were plated in time-point triplicates at 20,000 cells per well in 96-well clear bottom plates in medium with and without puromycin. Cells without puromycin were assessed 4 h after plating to establish baseline absorbance for each target. Cell survival was assessed at day 2, day 5, and day 7 after transfection using the CellTiterGlow reagent (Promega, 1:10 dilution of suggested reagent). Luminescence at 135-nm absorbance was measured using a Synergy plate reader (Biotek Instruments). Nucleic acid sampling and sequencing library production. For obtaining wildtype HAP1 genomic DNA for cloning homology arms and for genotyping the HAP1-LIG4 KO cell line, DNA was isolated using the DNeasy kit (Qiagen). For each SGE experiment, DNA and total RNA were purified using the AllPrep kit (Qiagen). DNA samples were quantified with the Qubit dsDNA Broad Range kit (Thermo Fisher) and RNA samples by UV spectrometry (Nanodrop). PCR primers for genomic DNA were designed such that one primer would anneal outside of the homology arm sequence, thereby selecting for amplicons derived from gDNA and not plasmid DNA. PCR conditions were optimized using gradient qPCR on wild-type HAP1 gDNA.
All gDNA collected from the population of day-5 cells was sampled by performing many PCR reactions in parallel on a 96-well plate, using 250 ng of gDNA per 50 μl reaction such that all day-5 gDNA was used in PCR (Kapa HiFi). At least as many PCR reactions were performed for day-11 samples (which yielded more gDNA) to ensure adequate sampling. PCRs were performed for the minimal number of cycles needed to complete amplification, with cycling conditions as specified in the Kapa HiFi protocol. An additional PCR was performed using day-5 gDNA from negative control transfections for each exon.
After PCR, multiple wells of amplicons from the same sample were pooled and purified using Ampure beads. Next, a nested qPCR was performed using the first reaction as template to produce a smaller amplicon with custom sequencing adapters ('PU1L' and 'PU1R'), which was likewise purified with Ampure beads. The SGE libraries were also PCR-amplified at this step, starting from 50 ng of plasmid DNA. Lastly, a final qPCR was performed using purified products from the second reaction as template to add dual sample indexes and flow cell adapters.
Article reSeArcH
RNA was sampled from day-5 HAP1-LIG4 KO cells (AllPrep, Qiagen). Reverse transcription followed by RNase H treatment was performed on all collected RNA or a maximum of 5 μg per sample (Superscript IV Kit, Life Technologies). This reaction was primed with a gene-specific primer complementary to the 3′ UTR in exon 23 of BRCA1. Primers were designed for each exon to amplify across exon junctions, and reaction conditions were optimized using gradient PCR. cDNA was distributed into five equal PCR reactions, which were run on a qPCR machine and then pooled in equal ratios. Flow cell adapters and sample indexes were added in an additional reaction (as for gDNA samples).
All sequencing libraries were purified with Ampure beads, quantified with the Qubit dsDNA High Sensitivity kit (Life Technologies), diluted and denatured for sequencing in accordance with protocols for the Illumina NextSeq or MiSeq machines. Sequencing and data analysis. Sequencing was performed on an Illumina NextSeq or MiSeq instrument, allocating about 3 million reads to each gDNA and cDNA sample, 1 million reads for each HDR library, and 500,000 reads for each negative control sample. gDNA samples for individual exons were sequenced on the same run. In total, 300 cycle kits were used, with 150 cycles for read 1 and read 2 each, and 19 cycles for dual index reads. Custom sequencing primers and indexing primers are provided in Supplementary Table 3 . Illumina PhiX control DNA was added to each sequencing run (around 10% MiSeq, around 30-40% NextSeq) to improve base calling.
We used bcl2fastq 2.16 (Illumina) to call bases and perform sample demultiplexing and fastqc 0.11.3 was run on all samples to assess sequencing quality. SeqPrep was used with the following parameters to perform adapter trimming and to merge perfectly matched overlapping read pairs: '-A GGTTTGGAGCGAGATTGATAAAGT -B CTGAGCTCTCTCACAGCCATTTAG -M 0.1 -m 0.001 -q 20 -o 20' . Merged reads containing 'N' bases were removed. Reads from cDNA samples were removed if they contained indels or did not perfectly match transcript sequence flanking each targeted exon. Remaining cDNA reads were processed to match genomic DNA amplicons by removing flanking exonic sequence and replacing it with the exon's corresponding intronic sequence. All reads were then aligned to reference gDNA amplicons for each exon using the needleall command in the EMBOSS 6.4.0 package with the following parameters: '-gapopen 10 -gapextend 0.5 -aformat sam' . Reads not aligning to the reference amplicon (alignment score, <300) were removed from analysis. To analyse indels, unique cigar counts were quantified from day-5 and day-11 samples using a custom Python script. Reads were classified as HDR events for rate calculations if the programmed edit or edits to the PAM or protospacer (HDR marker edits) were observed in the alignment. Variants without identifiable markers of HDR were not used. Abundances of SNVs were quantified only from aligned reads that had no other mismatches or indels, with the exception of the HDR markers. SNV reads with only the cut-site proximal HDR marker were summed with reads that had both HDR markers to get total abundances for each SNV in each sample, to which a pseudocount of 1 was added to all variants present in either the library, day-5 or day-11 sample. Frequencies for each SNV were calculated as SNV reads over total reads. SNV measurements from wild-type HAP1 cells and HAP1-LIG4 KO cells were processed separately at all steps. Specific exon 2 splice junctions were queried by counting the number of reads from cDNA samples that perfectly matched specific isoform junctions. Two 14-bp sequences spanning the end of exon 1 and the beginning of exon 2 were counted to measure use of the canonical junction (5′-TCTGGTTCATTGGA-3′ and 5′-TCTGGTTCACTGGA-3′; the latter of which contains an HDR marker introduced during editing). The 14-bp sequence spanning the end of exon 1 and the portion of exon 2 corresponding to the reported alternative AG acceptor site 45, 46 was (5′-TAAAGAAAGAAATG-3′). The proportion of the total reads counted containing the latter sequence was used to approximate the relative contribution of the alternative acceptor site.
Modelling positional biases of library integration. Positional biases in editing rates were modelled for each SNV by using a LOESS regression to fit the log 2 day 5 over library ratios as a function of chromosomal position. To avoid modelling biological effects instead of positional effects, the model was fit only on the subset of SNVs that were not substantially depleted between any two time points in the experiment (that is, SNVs with day 5 over library ratios greater than 0.5 and day 11 over day 5 ratios greater than 0.8.). The regression was performed for each exon replicate, using the 'loess' function in R with span = 0.15. Each model was extended flatly outward to include any positions not fit (a total of 22 nucleotides of sequence on the edges of the edited regions). We subtracted positional fit (the model's output) for each SNV from its log 2 day 11 over library ratio to get position-adjusted ratios for each SNV. Normalizing scores within and across exons. Position-adjusted log 2 day 11 over library ratios were normalized first across exon replicates, and then across all assayed exons. To do this, scores from within each replicate were linearly scaled such that the median synonymous and median nonsense SNVs within the replicate would match the median synonymous and median nonsense SNV values averaged across replicate experiments. The ensuing SNV scores for each replicate were then normalized across all exons in the same manner, such that each exon's median synonymous and median nonsense SNV scores would match the global median synonymous and the global median nonsense SNV scores, respectively. SNV functional class assignment. Function scores were averaged across replicates and a mixture model was used to estimate the probability that each SNV's score was drawn from the non-functional distribution of scores. The non-functional distribution was defined as nonsense SNVs across all exons. The functional distribution was defined as exonic synonymous SNVs not within 3 bp of splice junctions and with RNA scores within 1 standard deviation of the median synonymous SNV. This definition does not fully guarantee that these SNVs have no functional consequence. The means and variances of the 'non-functional' and 'functional' groups were fixed and a model was fit using the normalmixEM function of the mixtools package in R, with starting component proportions set to 0.5. The posterior probabilities generated from the model were used as point estimates of the probability of drawing each SNV's score from the non-functional distribution (P nf ). Functional classifications were made by setting thresholds for P nf as follows: P nf > 0.99 = 'non-functional' , 0.01< P nf < 0.99 = 'intermediate' ,
Independent of mixture modelling, ROC curves were used to assess performance of SGE data and other metrics' ability to predict assigned ClinVar classifications. These analyses were performed with the 'plotROC' package in R, and Youden's J-statistic (sensitivity plus specificity minus 1) was calculated to determine optimal values reported in text. Variant filtering. A small minority of SNVs that could not be accurately scored were removed from analysis. If a SNV was not present in the HDR library at a frequency over 1 in 10 4 , it was presumed to have been lost in oligonucleotide synthesis or cloning and was removed. Further, if a SNV was not observed with complete HDR markers at a frequency over over 1 in 10 5 in day-5 genomic DNA samples from both replicate experiments, it was removed. SNVs introduced near the CRISPR recognition site have the potential to facilitate Cas9 re-cutting of the locus (for example, by replacing the PAM edit or introducing an alternative PAM site). Because these SNVs are likely to score lower consequent to Cas9 editing biases and not their effects on gene function, SNVs were filtered that created increased potential for re-cutting as follows: When an HDR marker mutation used to disrupt editing occurred at position 2 of the PAM (for example, 'NGG' to 'NCG'), SNVs that replaced this marker with an alternate base were removed to prevent biases introduced by re-cutting non-canonical S. pyogenes Cas9 PAMs (for example, 'NAG' , 'NTG'). Additionally, variants that created a new PAM 1 bp 3′ of the mutated PAM were excluded owing to the potential for re-cutting (for example, unedited PAM: 5′-NGGA, edited PAM with HDR marker: 5′-NCGA, filtered out SNV that creates new PAM +1 bp 3′: 5′-NCGG). (Extended Data Figure 6 describes re-cutting observed at alternative PAMs.) To prevent misinterpretation, we also removed SNVs that created amino acid changes specific to the context of the library's fixed edits (for example, if in the unedited background, the SNV causes an X to Y change, but with a fixed edit in the same codon, the SNV causes an X to Z change). We also applied this logic to remove SNVs that introduced splice donor sites only in the context of the edited PAM, and SNVs that create splice donor sites in the unedited context but not in the context of the edited PAM.
The RNA scores for exon 18 samples were neither well-correlated across replicates nor with SNV abundances in genomic DNA, indicating probable bottlenecking in library preparation. Therefore, RNA data from exon 18 was excluded. Wild-type HAP1 function scores from exon 22 were excluded because there was an unusually high correlation between SNV frequencies sampled from the plasmid library and from day-5 gDNA, suggesting plasmid contamination in gDNA sequencing. This problem was fixed by designing a new primer to prepare gDNA sequencing samples from HAP1-LIG4 KO All studies must disclose on these points even when the disclosure is negative.
Sample size
No explicit calculations were performed to determine sample size. Rather, we aimed to test every possible nucleotide in each of the 13 BRCA1 exons that encode for the RING and BRCT domains. Therefore, in each transfection, the number of SNVs tested was roughly 3-fold the number of nucleotides in the exon tested (including some adjacent intron sequence), corresponding to all possible SNVs. Our achieved sampling is shown in Extended Data Fig. 3c .
To effectively sample each SNV in each experiment, we transfected cell populations large enough to maximize the chance every library SNV was introduced to the genome hundreds of times each (approximately 20,000,000 cells per experiment). Approximately 3.5% of SNV measurements were excluded. In short, data were excluded according to uniformly applied rules to ensure scores were reflective of experimental selection and not poor sampling and/or artifacts resulting from the genome editing process (Extended Data  Fig. 6a ).
Data exclusions
More specifically, to rule out artificial sampling from sequencing error, SNVs not adequately sampled on Day 5 (over 1 in 100,000 reads) were excluded. Certain SNVs located near Cas9 target sites made the enzyme more likely to re-cut the genome after editing, thereby artificially lowering the SNVs abundance (Extended Data Fig. 6b,c) . Additionally, SNVs that occurred near HDR marker mutations and due to this, caused different amino acid sequence changes or had greater potential to disrupt splicing were also excluded.
RNA data for exon 18 was excluded due to a lack of reproducibility across replicates (Extended Data Fig. 4) , and exon 22 WT data was excluded due to primer cross-reactivity that led to an uncharacteristically high correlation between plasmid library measurements and Day 5 measurements (Extended Data Fig. 4a ).
Replication
All SGE experiments were performed at least two times to assess reproducibility, which is described in Extended Data Fig. 4 . A small fraction of SNVs scored discordantly between replicates were removed from the data set (n=14 SNVs, Extended Data Fig. 6a ).
Two replicates were obtained in both WT HAP1 cells, and HAP1-Lig4KO cells. Results between cell lines also showed a high correlation (Extended Data Figs. 3i and 10c ).
Randomization Variants were tested in multiplex, with hundreds of variants related by physical proximity in the genome per sample.
Blinding
Function scores for each variant were determined without knowledge of known pathogenicity status, which was only assessed after.
Reporting for specific materials, systems and methods No commonly misidentified cell lines were used.
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Methodology
Sample preparation Cell population abundance The haploid, 1N population was 29%
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